|The following article is part of live conference coverage from the 2017 American Epilepsy Society Annual Meeting in Washington, DC. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AES 2017.|
WASHINGTON, DC – Approximately one-third of pediatric patients with refractory convulsive status epilepticus (RSE) develop neurologic deficits, according to findings from a multicenter, prospective, observational study presented at the 2017 American Epilepsy Society Annual Meeting, December 1-5, 2017 in Washington, DC.
A total of 163 pediatric patients with RSE who had ≥1-year follow-up data available were included in this observational analysis. For this study, the primary outcome was comprised of new neurologic deficit developments during follow-up.
At median follow-up of 2.1 years, 142 patients were taking a median of 2 antiseizure medications. Of these patients, 109 continued to have unprovoked seizures. Additionally, 60 of 77 patients who had no prior epilepsy history were administered antiseizure medications during the follow-up period.
The researchers found that 26 patients presented with additional episodes of RSE at follow-up, whereas a total of 84 patients had a need for rescue therapy at least once. Repeated episodes of RSE occurred in 16 of the 127 patients who had no clinical history of RSE.
During the follow-up period, new neurologic deficits developed in 36 patients. According to findings from a multivariate analysis, the duration of RSE represented the only significant predictor for the development of new neurologic deficits (P =.04). Patients who developed neurologic deficits had a significantly longer duration of RSE compared with those who did not (27.75; 95% CI, 1.75-144 h vs 3.68; 95% CI, 2-13 h, respectively; P =.023).
The investigators concluded that the duration of RSE may provide predictive value for future neurologic issues.